Globus Medical Inc. | Globus Medical | medical equipment and supplies | off-label or unapproved promotion of medical products | 2012 | FDA | $550,000 |
Endo Health Solutions Inc. | Endo International | pharmaceuticals | off-label or unapproved promotion of medical products | 2014 | FDA | $192,700,000 |
Johnson & Johnson | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | FDA | $2,200,000,000 |
Wyeth Pharmaceuticals Inc. | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | FDA | $490,900,000 |
Par Pharmaceutical Companies Inc. | Endo International | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | FDA | $45,000,000 |
GlaxoSmithKline LLC | GlaxoSmithKline | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | FDA | $3,000,000,000 |
Abbott Laboratories Inc. | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | FDA | $1,500,000,000 |
Cypress Pharmaceutical Inc. | Currax Pharmaceuticals | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | FDA | $2,800,000 |
Merck, Sharp & Dohme | Merck | pharmaceuticals | off-label or unapproved promotion of medical products | 2011 | FDA | $950,000,000 |
Pfizer Inc. | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2011 | FDA | $14,500,000 |
Scios Inc. | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2011 | FDA | $85,000,000 |
Novo Nordisk Inc. | Novo Holdings A/S | pharmaceuticals | off-label or unapproved promotion of medical products | 2011 | FDA | $25,000,000 |
UCB Inc. | UCB | pharmaceuticals | off-label or unapproved promotion of medical products | 2011 | FDA | $34,000,000 |
Forest Pharmaceuticals Inc. | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2011 | FDA | $164,000,000 |
Elan Corporation PLC | Perrigo | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | FDA | $203,000,000 |
Eisai Inc. | Eisai | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | FDA | $11,000,000 |
Novartis Pharmaceuticals Corporation | Novartis | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | FDA | $422,500,000 |
Allergan Inc. | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | FDA | $600,000,000 |
Ortho-McNeil Pharmaceutical LLC | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | FDA | $81,000,000 |
AstraZeneca LP | AstraZeneca | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | FDA | $520,000,000 |
Amgen Inc. | Amgen | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | FDA | $762,000,000 |
Victory Pharma Inc. | | | off-label or unapproved promotion of medical products | 2012 | DOJ_CIVIL | $11,420,743 |
Inspire Pharmaceuticals Inc. | Merck | pharmaceuticals | off-label or unapproved promotion of medical products | 2015 | USAO | $5,900,000 |
Warner Chilcott PLC | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2015 | FDA | $125,000,000 |
Google Inc. | Alphabet Inc. | information technology | off-label or unapproved promotion of medical products | 2011 | FDA | $500,000,000 |
Shire Pharmaceuticals LLC | Takeda Pharmaceutical | pharmaceuticals | off-label or unapproved promotion of medical products | 2014 | FDA | $56,500,000 |
Healthpoint Ltd. and DFB Pharmaceuticals | | | off-label or unapproved promotion of medical products | 2012 | FDA | $28,000,000 |
Boehringer Ingelheim Pharmaceuticals Inc. | Boehringer Ingelheim | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | FDA | $95,000,000 |
Novartis Vaccines & Diagnostics Inc. and Novartis Pharmaceuticals Corporation | Novartis | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | FDA | $72,500,000 |
Atricure Inc. | AtriCure | medical equipment and supplies | off-label or unapproved promotion of medical products | 2010 | FDA | $3,760,000 |
Spectranetics Corporation | Royal Philips | diversified | off-label or unapproved promotion of medical products | 2009 | FDA | $5,000,000 |
Pfizer Inc. | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2009 | FDA | $2,300,000,000 |
Endoscopic Technologies Inc. | | | off-label or unapproved promotion of medical products | 2009 | DOJ_CIVIL | $1,400,000 |
Eli Lilly and Company | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2009 | FDA | $1,415,000,000 |
Cephalon Inc | Teva Pharmaceutical Industries | pharmaceuticals | off-label or unapproved promotion of medical products | 2008 | FDA | $425,000,000 |
Otsuka American Pharmaceutical Inc. | Otsuka Pharmaceutical | pharmaceuticals | off-label or unapproved promotion of medical products | 2008 | FDA | $4,000,000 |
Bristol-Myers Squibb Company | Bristol-Myers Squibb | pharmaceuticals | off-label or unapproved promotion of medical products | 2007 | DOJ_CIVIL | $515,000,000 |
Medicis Pharmaceutical Corporation | Bausch Health | pharmaceuticals | off-label or unapproved promotion of medical products | 2007 | DOJ_CIVIL | $9,800,000 |
Cell Therapeutics Inc. | | | off-label or unapproved promotion of medical products | 2007 | FDA | $10,500,000 |
Serono, S.A. | Merck KGaA (EMD) | pharmaceuticals | off-label or unapproved promotion of medical products | 2005 | FDA | $704,000,000 |
Warner-Lambert | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2004 | FDA | $430,000,000 |
Eli Lilly and Company | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2005 | FDA | $36,000,000 |
InterMune Inc. | Roche | pharmaceuticals | off-label or unapproved promotion of medical products | 2006 | FDA | $36,900,000 |
SB Medical Inc. and TC Medical Group | | | off-label or unapproved promotion of medical products | 2015 | USAO | $75,000,000 |
Janssen Pharmaceuticals, Inc. | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | USAO | $410,000,000 |
GeneScience Pharmaceutical Company | | | off-label or unapproved promotion of medical products | 2010 | USAO | $7,500,000 |
Specialty Distribution Services Inc. | | | off-label or unapproved promotion of medical products | 2007 | USAO | $10,500,000 |
Jazz Pharmaceuticals Inc. | Jazz Pharmaceuticals | pharmaceuticals | off-label or unapproved promotion of medical products | 2007 | USAO | $20,000,000 |
Schering-Plough Corporation | Merck | pharmaceuticals | off-label or unapproved promotion of medical products | 2006 | USAO | $435,000,000 |
Abbott Laboratories | Abbott Laboratories | pharmaceuticals | off-label or unapproved promotion of medical products | 2018 | USAO | $25,000,000 |
Carefusion Corporation | Becton Dickinson | medical equipment and supplies | off-label or unapproved promotion of medical products | 2019 | USAO | $3,300,000 |
Abbott Laboratories | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $339,148,643 |
Allergan Inc. | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $14,750,000 |
Amgen Inc. | Amgen | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $612,000,000 |
Amgen Inc. | Amgen | pharmaceuticals | off-label or unapproved promotion of medical products | 2015 | MULTI-AG | $71,000,000 |
AstraZeneca | AstraZeneca | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | KY-AG | $5,500,000 |
AstraZeneca Pharmaceuticals | AstraZeneca | pharmaceuticals | off-label or unapproved promotion of medical products | 2011 | MULTI-AG | $68,500,000 |
AstraZeneca Pharmaceuticals LP | AstraZeneca | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $218,092,993 |
Boehringer Ingelheim Pharmaceuticals, Inc. | Boehringer Ingelheim | pharmaceuticals | off-label or unapproved promotion of medical products | 2017 | MULTI-AG | $13,500,000 |
Boehringer-Ingelheim Pharmaceuticals, Inc. | Boehringer Ingelheim | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $95,000,000 |
Bristol-Myers Squibb | Bristol-Myers Squibb | pharmaceuticals | off-label or unapproved promotion of medical products | 2016 | MULTI-AG | $19,500,000 |
CareFusion | Becton Dickinson | medical equipment and supplies | off-label or unapproved promotion of medical products | 2014 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $40,100,000 |
Celgene Corp. | Bristol-Myers Squibb | pharmaceuticals | off-label or unapproved promotion of medical products | 2017 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $20,700,000 |
Cephalon Inc. | Teva Pharmaceutical Industries | pharmaceuticals | off-label or unapproved promotion of medical products | 2008 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $116,000,000 |
Cephalon, Inc. | Teva Pharmaceutical Industries | pharmaceuticals | off-label or unapproved promotion of medical products | 2008 | CT-AG | $6,150,000 |
Eisai Inc. | Eisai | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $4,658,249 |
Elan Corp. | Perrigo | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $43,399,040 |
Eli Lilly | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | AR-AG | $18,500,000 |
Eli Lilly | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | MS-AG | $18,500,000 |
Eli Lilly | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | LA-AG | $20,000,000 |
Eli Lilly and Co. | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2009 | CT-AG | $25,100,000 |
Eli Lilly and Co. | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2009 | ID-AG | $13,000,000 |
Eli Lilly and Company | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2009 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $361,828,456 |
Eli Lilly and Company | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2008 | MULTI-AG | $62,000,000 |
Endo Health Solution | Endo International | pharmaceuticals | off-label or unapproved promotion of medical products | 2014 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $173,000,000 |
Florida Men's Medical Clinic, LLC and Men's Medical Clinic, LLC | | | off-label or unapproved promotion of medical products | 2016 | MA-AG | $17,000,000 |
Genentech Inc. | Roche | pharmaceuticals | off-label or unapproved promotion of medical products | 2000 | MULTI-AG | $19,000,000 |
GlaxoSmithKline | GlaxoSmithKline | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $477,792,391 |
GlaxoSmithKline | GlaxoSmithKline | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | KY-AG | $3,700,000 |
GlaxoSmithKline | GlaxoSmithKline | pharmaceuticals | off-label or unapproved promotion of medical products | 2009 | KY-AG | $661,860 |
Healthpoint Ltd. | | | off-label or unapproved promotion of medical products | 2013 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $28,000,000 |
Inspire Pharmaceuticals | Merck | pharmaceuticals | off-label or unapproved promotion of medical products | 2015 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $6,000,000 |
Insys | | | off-label or unapproved promotion of medical products | 2015 | OR-AG | $1,100,000 |
Insys Therapeutics Inc. | | | off-label or unapproved promotion of medical products | 2017 | IL-AG | $4,450,000 |
Insys Therapeutics, Inc. | | | off-label or unapproved promotion of medical products | 2017 | MA-AG | $500,000 |
InterMune Inc. | Roche | pharmaceuticals | off-label or unapproved promotion of medical products | 2006 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $6,700,000 |
ISTA Pharmaceuticals, Inc. | Bausch Health | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $390,253 |
Janssen Ortho LLC and Janssen Pharmaceuticals, Inc. | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2014 | MT-AG | $5,900,000 |
Janssen Pharmaceuticals, Inc. | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | $181,000,000 |
Janssen Pharmaceuticals, Inc. | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | MA-AG | $15,100,000 |
Johnson & Johnson | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $541,000,000 |
Johnson & Johnson | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | TX-AG | $158,000,000 |
Medicis Pharmaceutical Corporation | Bausch Health | pharmaceuticals | off-label or unapproved promotion of medical products | 2007 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $4,000,000 |
Merck Sharp & Dohme Corp. | Merck | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $201,975,000 |
Mylan Specialty, L.P. | Viatris | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | MA-AG | $250,000 |
Novartis Pharmaceuticals Corporation | Novartis | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $88,258,694 |
Novartis Vaccines & Diagnostics Inc. and Novartis Pharmaceuticals Corporation | Novartis | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $29,000,000 |
Novartis Pharmaceuticals | Novartis | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | TX-AG | $6,638,250 |
Novo Nordisk Inc. | Novo Holdings A/S | pharmaceuticals | off-label or unapproved promotion of medical products | 2011 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $3,574,209 |
Organon | Organon & Co. | pharmaceuticals | off-label or unapproved promotion of medical products | 2014 | MULTI-AG | $31,000,000 |
Ortho-McNeil Pharmaceutical LLC | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $24,681,516 |